NCT06725537Not yet recruiting
Comprehensive Demographics and Clinical Profile of NSCLC Patients
Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Treatment Patterns With PD-L1 Stratification
Source: ClinicalTrials.gov · Last updated 15 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options. The molecular biology of the disease, biomarkers and the patient's clinical characteristics can assist in decision making. The study in question aims to retrospectively evaluate the patterns of choice in the first line treatment of metastatic non-small cell lung cancer without driver mutations, from 2019 to 2022 in 7 centers in Brazil.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 5 Dec 2024
- Start date
- 20 Jan 2025
- Primary completion date
- 1 Mar 2025
- Lead sponsor
- D'Or Institute for Research and Education
- Diseases
- Lung cancer
- NCT number
- NCT06725537
What you commit to
- Study type: Observational
- Planned participants: 500
- From 20 Jan 2025 to the primary completion date, 1 Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with localized disease that can be treated locally;
Other
- Non-epithelial histology;
- small cell carcinoma
- neuroendocrine tumor
Who the study is looking for
- Over 18 years old;
- Histological diagnosis of advanced non-small cell cancer;
- Clinical and demographic data available in medical records;
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.